Editor\'s NotesBackground and ContextEGFR inhibitors are used in combination with chemotherapy in a subset of metastatic colorectal cancer patients. However, therapy response does not correlate to EGFR expression in tumor cells.New FindingsThe researchers show that EGFR expression and activation in myeloid cells promotes colorectal cancer in mice and correlate with bad prognosis in metastatic colorectal cancer patients.LimitationsThe exact myeloid cell population expressing EGFR, thereby influencing tumor growth is yet unknown.ImpactEGFR expression in myeloid cells is a novel biomarker for the prognosis of colorectal cancer.

Colorectal cancer (CRC) is the third most common cancer in the United States with 5-year survival rates less than 15% for patients with metastasis.[@bib1] CRC originates from intestinal epithelial cells (IECs) at the crypt base due to multistage loss of tumor suppressor genes---especially *APC*---with concomitant accumulation of activating oncogenic mutations, such as in the *KRAS* gene.[@bib2] Besides heritable genetic alterations and environmental factors, one risk factor for tumor development is inflammatory bowel disease, leading to so-called colitis-associated cancer (CAC).[@bib3] As first-line treatment of metastatic CRC, combinations of chemotherapies together with targeted therapies like angiogenic (vascular endothelial growth factor) inhibitors and anti--epidermal growth factor receptor (EGFR) antibodies are used.[@bib4]

The EGFR is a receptor tyrosine kinase that is implicated in a variety of epithelial cancers by controlling cellular proliferation, differentiation, barrier integrity, and survival.[@bib5] 60%--80% of patients with CRC overexpress EGFR, which is associated with poor prognosis.[@bib6] Targeted inhibition of EGFR using monoclonal antibodies like cetuximab and panitumumab, represents one of the standard therapies of metastatic CRC and---combined with chemotherapies---provides survival benefit over chemotherapy alone.[@bib7] However, treatment response is limited to patients without activating *KRAS* mutations.[@bib4] Interestingly, treatment response does not correlate with the levels of EGFR expression in tumor cells. There also are a considerable number of nonresponders to anti-EGFR therapies in patients with *KRAS* wild-type state,[@bib8] highlighting the complex and converse roles of EGFR in CRC development.

Several studies indicate a protective role of EGFR in CRC. Using the *IL10*^*−/−*^ mouse model of CAC, it was shown that reduced EGFR signaling in the antimorphic *Egfr^wa5/+^* or the hypomorphic *Egfr*^*wa2/wa2*^ background[@bib9], [@bib10] augments colitis severity and accelerates and increases tumor development. Furthermore, azoxymethane/dextran sodium sulfate (AOM/DSS)-induced CAC is more invasive in *Egfr^wa5/+^* mice[@bib11] and *Egfr*^*wa2/wa2*^ mice exhibit increased severity of DSS- or oxazolone-induced colitis.[@bib12], [@bib13] In a clinical trial, localized EGFR stimulation alleviates symptoms of colitis.[@bib14] Different studies also support a pro-tumorigenic role of EGFR: diminished EGFR signaling in *Egfr*^*wa2/wa2*^ mice or by treatment with pharmacological EGFR inhibitors reduces tumor formation in the AOM/DSS model of CAC and in the *Apc*^*Min*^ model of intestinal tumorigenesis.[@bib15], [@bib16], [@bib17] Finally, patient data show that EGFR is required for formation of aberrant crypt foci.[@bib18]

However, it is unknown how the influence of EGFR on tumorigenesis depends on the cell type from which it is expressed. Interestingly, reduced EGFR signaling in all cells by use of *Egfr*^*wa2*^ mice leads to defective intestinal adaptation after small bowel resection, whereas conditional EGFR deletion in IECs neither affects adaptation[@bib19] nor severity of DSS- or oxazolone-induced colitis.[@bib13] Conversely, lack of EGFR selectively in myeloid cells reduces severity of DSS-induced colitis.[@bib20] These observations collectively point toward a role of EGFR in nonepithelial cells of the intestine, namely myofibroblasts and monocytes/macrophages of the lamina propria (LP), in which EGFR expression has been reported.[@bib21], [@bib22]

Macrophages are common in CRC and influence tumor behavior at multiple levels.[@bib23] Their function seems to be dependent on tissue, location, and microenvironment, as both positive and negative outcomes of CRC have been associated with macrophage infiltration.[@bib24], [@bib25], [@bib26], [@bib27] Interleukin 6 (IL6) production by macrophages has been implicated in the prognosis of CAC, as IL6-deficient mice show reduced tumor burden.[@bib28] Moreover, elevated serum levels of IL6 directly correlate with poor clinical prognosis in different human cancers.[@bib29] Recently we could demonstrate in a mouse model of chemically induced hepatocellular carcinoma (HCC) that EGFR expression in tissue-resident liver macrophages (Kupffer cells) plays a tumor-promoting role by regulating IL6 production in response to tissue injury and thus HCC formation. Further, EGFR expression in Kupffer cells of patients with HCC correlates with poor prognosis.[@bib30]

In this study, we screened human CRC tumor biopsies for the presence of EGFR-positive myeloid cells to analyze if this impinges on disease outcome. Moreover, by using mouse models, we investigated in which specific cell type EGFR is required for colitis and CAC as well as oncogene-driven CRC development. We demonstrate that EGFR is expressed on myeloid cells within the tumor of patients with CRC which negatively affects overall survival of patients with metastatic CRC. In mice, expression of EGFR in myeloid cells, but not in IECs, promotes AOM/DSS-induced CAC and *Apc*^*Min*^-dependent intestinal tumorigenesis and protects from DSS-induced colitis in an IL6-dependent manner. This study provides mechanistic insight into the complex cell type--specific role of EGFR in CRC and finally marks a step toward the improvement of individualized cancer treatment.

Methods {#sec1}
=======

Clinical Material {#sec1.1}
-----------------

Histological blocks of 124 patients diagnosed with CRC, who had undergone surgical resection without any preoperative treatment between 2008 and 2011, were selected to obtain tissue microarrays (TMA) on informed consent as described.[@bib31] From the most representative areas of each donor tissue sample, a single core with a diameter of 2 mm was arranged into one recipient paraffin block (3.0 × 2.5 cm) using a semiautomatic tissue arrayer (Galileo TMA, Isenet, LLC, Philadelphia, PA). All cases were diagnosed at National Cancer Institute Fondazione 'G. Pascale' of Naples and at Medical Oncology, Seconda Università degli Studi of Naples, and staged according to the TNM classification (version dependent on year of diagnosis). Clinicopathological characteristics including demographics and staging features were evaluated. EGFR expression scores were obtained from immunohistochemistry (IHC) staining by 2 independent persons by intensity. For all analyses, the same TMAs were used. Due to different dropping out of cores, patient numbers varied slightly among the histological analyses.

Colitis and Tumorigenesis {#sec1.2}
-------------------------

Colitis was induced by administering 2.5% DSS (0216011080; MP Biomedicals, Santa Ana, CA) in autoclaved drinking water for 5 days followed by 5 days of normal water. Colon tumors were induced as described with mild modifications.[@bib32] Briefly, mice were injected intraperitoneally (IP) with 7.5 mg/kg AOM (A5486; Sigma-Aldrich, St. Louis, MO) followed by regular diet and water for 5 days. After that, mice received water with 2.5% DSS for 5 days, followed by maintenance on regular water for 16 days and 2 additional DSS cycles (5 days of 2.5% DSS and 4 days of 2% DSS). Mice were sacrificed 9 days after the last treatment. For inducible EGFR deletion after tumor development, 33 days after AOM, mice were injected IP with 1 mg tamoxifen (sunflower seed oil/ethanol mixture, 10:1; Sigma-Aldrich)[@bib33] for 5 days, followed by tamoxifen injection every 2 days until analysis. Recombinant murine IL6 (12340065; ImmunoTools, Friesoythe, Germany) or vehicle was administered as described.[@bib34], [@bib35] For IL6 depletion, mice were injected with 100 μg anti-mouse IL6 antibody and isotype (12-4301; Thermo Fisher Scientific, Waltham, MA), respectively.

Additional Methods {#sec1.3}
------------------

All further methods can be found in the [Supplementary Materials and Methods](#appsec1){ref-type="sec"} section.

Results {#sec2}
=======

EGFR Expression in Myeloid Cells Is a Prognostic Factor for Metastatic CRC {#sec2.1}
--------------------------------------------------------------------------

We have previously shown that presence of EGFR in tumor-associated macrophages (EGFR^+^ TAMs) in patients with HCC correlated with decreased disease-free and overall survival.[@bib30] Therefore, we investigated 116 human TMA samples of patients with surgically resected CRC for EGFR expression in both stromal and tumor cells by IHC ([Figure 1](#fig1){ref-type="fig"}*A*). EGFR expression was highly variable in intensity and location and patients could be subdivided into 4 groups: (1) positive in tumor and stroma; (2) negative in tumor and positive in stroma; (3) positive in tumor and negative in stroma; or (4) negative in tumor and stroma, with more than 60% of patients belonging to group 1 ([Figure 1](#fig1){ref-type="fig"}*A* and *B*). To visualize differences in EGFR expression in stroma and tumor, samples were further classified as IHC score +++ (n = 15), ++ (n = 34), + (n = 50), and − (n = 17) for tumor cells and IHC score +++ (n = 2), score ++ (n = 30), + (n = 57), and − (n = 27) for stromal cells according to the respective staining intensity ([Figure 1](#fig1){ref-type="fig"}*C*, [Supplementary Figure 1](#figS1){ref-type="fig"}*A*). With respect to group classification according with EGFR expression in stroma and tumor, correlation analyses showed no association with clinicopathological features, with exception of metastatic status at diagnosis (*P* = .03) ([Supplementary Table 1](#appsec2){ref-type="sec"}*A*). No correlation between any clinical parameter and EGFR intensity in tumor or stromal cells was found ([Supplementary Table 1](#appsec2){ref-type="sec"}*B*,*C*). Next, we investigated by immunofluorescence if specific stromal cell types showed EGFR expression. We performed double staining for EGFR and the macrophage marker CD68 as well as for the pan myeloid marker CD11b. Most of the analyzed samples showed presence of CD68^+^ (n = 114/118) or CD11b^+^ (n = 106/108) cells in the stromal compartment ([Figure 1](#fig1){ref-type="fig"}*F*). The presence of CD68^+^/EGFR^+^ and CD11b^+^/EGFR^+^ double positive cells varied highly, with 60% and 36% being the maximum of the total CD68^+^ and CD11b^+^ cell population, respectively ([Supplementary Figure 1](#figS1){ref-type="fig"}*B*). Staining for tyrosine-1068-phosphorylated EGFR (pEGFR) showed a strong correlation between EGFR expression and its phosphorylation, indicating that EGFR in myeloid cells is indeed activated ([Supplementary Figure 1](#figS1){ref-type="fig"}*B*--*D*). To stratify patients for the absence or presence of EGFR in myeloid cells or TAMs, samples were scored as negative (−) if they contained less than 1% and as positive (+) if they contained ≥1% of double positive cells out of the respective total number of CD68^+^ TAMs or CD11b^+^ myeloid cells. According to this classification, 73 samples were negative and 45 were double positive for CD68 and EGFR ([Figure 1](#fig1){ref-type="fig"}*D*), and 49 samples were negative and 59 were double positive for CD11b and EGFR ([Figure 1](#fig1){ref-type="fig"}*E*). When correlating these results with patient data, CD68^+^/EGFR^+^ cells did not show any association with clinicopathological features. However, moderately differentiated tumors (G2) displayed a higher percentage of double positive CD11b^+^/EGFR^+^ cells compared with less differentiated tumors (G3) (*P* = .03) ([Supplementary Table 1](#appsec2){ref-type="sec"}*D,E*). The distribution of double positive myeloid cells was comparable among the 18 patients with known RAS status. From the patients with wild-type RAS, 5 of 9 scored positive (\>1%) for CD11b^+^/EGFR^+^ cells and similarly, 6 of 9 patients were positive among the patients with mutated RAS ([Figure 1](#fig1){ref-type="fig"}*G*). In the total population, overall survival was not influenced by the presence of CD68^+^/EGFR^+^ or CD11b^+^/EGFR^+^ cells ([Figure 1](#fig1){ref-type="fig"}*H* and *I*). In patients with metastatic disease (at diagnosis or during follow-up), no correlation was found between survival and presence of CD68^+^/EGFR^+^ double positive TAMs ([Figure 1](#fig1){ref-type="fig"}*J*). However, metastatic patients showed significantly reduced overall survival with CD11b^+^/EGFR^+^ double positive cells in their tumors when compared with those who were negative ([Figure 1](#fig1){ref-type="fig"}*K*), suggesting that the presence of EGFR^+^ myeloid cells and not of just TAMs is negatively affecting overall survival of patients with metastatic CRC.Figure 1EGFR expression in CD11b^+^ myeloid cells reduces overall survival of patients with metastatic CRC. (*A*) IHC showing EGFR expression in human CRC. Four different EGFR staining patterns: (1) tumor/stroma EGFR positive, (2) tumor negative/stroma positive, (3) tumor positive/stroma negative, (4) tumor and stroma negative. *Scale bars* 50 μm. (*B*) Patient stratification according to staining patterns shown in (*A*) (n = 116). (*C*) Patient stratification according to immunohistochemical EGFR expression intensity in tumor (Tu) and stromal (Str) cells (n = 116). (*D*, *E*) Patients were divided into 2 groups: low (0 to \<1%) and high (≥1%), according to percentage of (*D*) CD68^+^/EGFR^+^ in the total CD68^+^ stromal population (n = 118) and (*E*) CD11b^+^/EGFR^+^ cells in the total CD11b^+^ stromal population (n = 108), determined by immunofluorescence shown in (*F*). (*F*) Immunofluorescence double staining on CRC samples shows presence of both CD68^+^/EGFR^+^ (*upper panel*) and CD11b^+^/EGFR^+^ (*lower panel*) cells in the stroma. *Scale bars* 50 μm. (*G*) Distribution of CD11b^+^/EGFR^+^ (0: 0 to \<1%; 1: ≥1%) among Patients with CRC with wild-type or mutant RAS. (*H*--*K*) Overall survival (OS) of all (*H* and *I*) and metastatic (*J* and *K*) patients with CRC with low (0 to \<1%) or high (≥1%) numbers of (*H* and *J*) CD68^+^/EGFR^+^ cells among the total CD68^+^ stromal population (general population: 118 patients; n = 73 with low and n = 45 with high counts, metastatic population: 45 patients; n = 31 with low and n = 14 with high counts) and (*I* and *K*) CD11b^+^/EGFR^+^ cells among the total CD11b^+^ stromal population (general population: 108 patients; n = 49 with low and n = 59 with high counts, metastatic population: 39 patients; n = 19 with low and n = 20 with high counts). Metastatic patients with high numbers of CD11b^+^/EGFR^+^ cells had a median OS of 26.2 months; 95% confidence interval, 9.1--43.4. Those with low CD11b^+^/EGFR^+^ numbers had a median OS of 50.2 months; 95% confidence interval, 22.0--78.2). \*\**P* = .005, log-rank test. neg, negative; pos, positive.

EGFR Signaling in Myeloid Cells Promotes Formation of CAC and *Apc*^*Min/+*^-driven Intestinal Tumors {#sec2.2}
-----------------------------------------------------------------------------------------------------

Because we observed that EGFR expression in myeloid cells correlated with patient overall survival, whereas expression in epithelial cells did not, we further investigated EGFR signaling in different intestinal cell populations during development of CAC in vivo. We used mouse models with conditional EGFR deletion in either IECs (*Egfr*^*ΔIEC*^) or myeloid cells (*Egfr*^*ΔMYL*^). *Egfr*^*ΔIEC*^ mice were generated by breeding *Egfr*^*f/f*^ mice with *Villin-Cre* mice that start to express *Cre* recombinase at approximately embryonic day 10.[@bib36] *Egfr*^*ΔMYL*^ animals were obtained by crossing *Egfr*^*f/f*^ animals with *LysM*^*Cre/+*^ mice, which express Cre recombinase in myeloid cells.[@bib37] As a comparison model for overall reduced EGFR signaling, we used hypomorphic *Egfr*^*wa2/wa2*^ mice.[@bib10] Successful EGFR deletion in IECs of *Egfr*^*ΔIEC*^ mice was shown by IHC, also demonstrating abundant EGFR expression in nonepithelial cells of the LP in both *Egfr*^*f/f*^ and *Egfr*^*ΔIEC*^ mice. Accordingly, IHC analysis did not show any EGFR expression in LP cells of *Egfr*^*ΔMYL*^ mice, whereas expression was maintained in IECs ([Supplementary Figure 2](#figS2){ref-type="fig"}*A*). IEC- and myeloid cell--specific EGFR deletion in *Egfr*^*ΔIEC*^ and *Egfr*^*ΔMYL*^ mice was confirmed by polymerase chain reaction, Southern blot, Western blot, and quantitative reverse-transcriptase polymerase chain reaction analysis in isolated IECs and cultured bone marrow--derived macrophages, respectively ([Supplementary Figure 2](#figS2){ref-type="fig"}*B*--*G*). All mice were viable and displayed no obvious gut abnormalities. Histological examination of adult *Egfr*^*wa2/wa2*^, *Egfr*^*ΔIEC*^, and *Egfr*^*ΔMYL*^ mice showed proper cellular composition and differentiation in both colon and small intestine ([Supplementary Figure 2](#figS2){ref-type="fig"}*H*), as shown previously.[@bib17], [@bib19], [@bib20] These data demonstrate that neither lack of EGFR in IECs or myeloid cells nor overall EGFR depletion affects intestinal structure or cell differentiation.

As chronic colitis is a significant risk factor for development of CRC, we applied the AOM/DSS model for CAC investigation ([Supplementary Figure 3](#figS3){ref-type="fig"}*A*).[@bib38] CAC developed in animals of all genotypes ([Figure 2](#fig2){ref-type="fig"}*A*) and CD64^+^/EGFR^+^ monocytes/macrophages were detected in all tumors except those derived from *Egfr*^*ΔMYL*^ mice ([Figure 2](#fig2){ref-type="fig"}*B*). Moreover, EGFR was activated in CD64^+^ cells of *Egfr*^*f/f*^ and *Egfr*^*ΔIEC*^ mice, as evidenced by the presence of CD64^+^/pEGFR^+^ double positive cells. No pEGFR was detectable in *Egfr*^*ΔMYL*^ mice ([Supplementary Figure 3](#figS3){ref-type="fig"}*B*). Tumor penetrance, area, load, and multiplicity were similar in *Egfr*^*ΔIEC*^ and *Egfr*^*f/f*^ mice ([Figure 2](#fig2){ref-type="fig"}*C*--*F*), suggesting that EGFR signaling in IECs is not required for CAC formation. In contrast, *Egfr*^*ΔMYL*^ mice with EGFR ablation in myeloid cells had a significantly lower tumor penetrance than controls ([Figure 2](#fig2){ref-type="fig"}*C*). Further, *Egfr*^*ΔMYL*^ animals exhibited significant reduction in tumor area, load, and multiplicity, with most tumors localized in the distal colon ([Figure 2](#fig2){ref-type="fig"}*A* and *D*--*F*). Tumor area and load of *Egfr*^*wa2/wa2*^ mice with hypomorphic EGFR alleles in all body cells were also significantly smaller than those of controls ([Figure 2](#fig2){ref-type="fig"}*D* and *E*), confirming previous studies[@bib15] and suggesting that myeloid cell--specific deficiency of EGFR signaling impairs CRC development. *Egfr*^*ΔIEC/ΔMYL*^ compound conditional knockout mice lacking EGFR in both IECs and myeloid cells had significantly reduced tumor number and size and significantly reduced overall tumor burden compared with *Egfr*^*f/f*^ mice ([Figure 2](#fig2){ref-type="fig"}*A* and *C*--*F*). As tumor development in *Egfr*^*ΔIEC/ΔMYL*^ mice was analogous to *Egfr*^*ΔMYL*^ mice, we concluded that EGFR signaling in myeloid cells is the major contributor to CAC oncogenesis. Tumors of all genotypes were predominantly low-grade adenomatous lesions, with *Egfr*^*ΔMYL*^ mice having the highest proportion. Only a minor percentage of tumors progressed to high-grade adenomas or adenocarcinomas ([Supplementary Figure 3](#figS3){ref-type="fig"}*C* and *D*). There was no difference in the histological inflammation score among genotypes ([Supplementary Figure 3](#figS3){ref-type="fig"}*E*). All genotypes showed comparable levels of proliferation ([Figure 2](#fig2){ref-type="fig"}*G*, [Supplementary Figure 3](#figS3){ref-type="fig"}*F*). However, the rate of apoptosis was significantly increased in tumors of *Egfr*^*ΔMYL*^ mice ([Figure 2](#fig2){ref-type="fig"}*H*, [Supplementary Figure 3](#figS3){ref-type="fig"}*E*). These data indicate that EGFR signaling in myeloid cells supports the survival of CRC cells, thereby promoting tumorigenesis.Figure 2EGFR signaling in myeloid cells promotes formation of colitis-associated and *Apc*^*Min*^-driven intestinal tumorigenesis. (*A*) Hematoxylin-eosin colon staining of AOM/DSS-treated mice. *Arrowheads* depict tumors. *Scale bars* 1 mm. (*B*) Immunofluorescence double staining of EGFR/CD64 on colorectal tumors. *Arrowheads* depict presence of EGFR^+^/CD64^+^ cells. *Scale bars* 50 μm. (*C*) Tumor penetrance in AOM/DSS-treated mice (ctrl \[control\], n = 10; *Egfr*^*wa2/wa2*^, n = 5; *Egfr*^*f/f*^, n = 22; *Egfr*^*ΔIEC*^ and *Egfr*^*ΔMYL*^, n = 15; *Egfr*^*ΔIEC/ΔMYL*^, n = 12). \**P* \< .05, \*\**P* \< .01, Fisher's exact test. (*D*--*F*) Analysis of tumor formation in AOM/DSS-treated mice (see \[*C*\] for number of mice). (*D*) Tumor area, (*E*) load (tumor area (×10^--2^)/colon area), and (*F*) multiplicity (number of tumors/cm^2^ colon area). (*G*) Proliferation index (BrdU-incorporated tumor cells/area, 9 tumors from 3 different mice were counted). Data are mean ± SEM. (*H*) Apoptotic index (cleaved Caspase-3^+^ tumor cells/area, 14--28 tumors from 3--6 different mice were counted). (*I*--*K*) Analysis of tumor formation in the *Apc*^*Min*^ background (*Apc*^*Min/+*^;*Egfr*^*wa2/+*^, n = 9; *Apc*^*Min/+*^;*Egfr*^*wa2/wa2*^, n = 8; *Apc*^*Min/+*^;*Egfr*^*f/f*^, n = 18; *Apc*^*Min/+*^;*Egfr*^*ΔIEC*^, n = 9; *Apc*^*Min/+*^;*Egfr*^*ΔMYL*^, n = 11). (*I*) Tumor area, (*J*) load, and (*K*) multiplicity. Data from (*D*--*K*) are mean ± SEM, \**P* \< .05, \*\**P* \< .01, *t* test. \# *P* \< .05, \#\# *P* \< .01, 1-way analysis of variance with Dunn's posttest.

To investigate the role of EGFR signaling in a colitis-independent intestinal tumor background, we used the *Apc*^*Min/+*^ model, in which we confirmed that reduced EGFR in all cells leads to tumor reduction.[@bib17] Similar to the AOM/DSS model, no change in tumor size, load, and multiplicity was observed in *Apc*^*Min/+*^*;Egfr*^*ΔIEC*^ mice when compared with *Apc*^*Min/+*^*;Egfr*^*f/f*^ controls. In contrast, deletion of EGFR in myeloid cells led to markedly reduced tumor size, load, and number in *Apc*^*Min/+*^*;Egfr*^*ΔMYL*^ animals ([Figure 2](#fig2){ref-type="fig"}*I*--*K*). Therefore, EGFR signaling in myeloid cells promotes intestinal tumor formation also in an oncogene-driven model of intestinal tumorigenesis.

Targeting EGFR in IECs of Established Tumors Does Not Lead to Tumor Shrinkage {#sec2.3}
-----------------------------------------------------------------------------

As targeted EGFR inhibition is one of the first-line treatments in metastatic CRC, we depleted EGFR in IECs after AOM/DSS-dependent tumor formation using the tamoxifen-inducible *Villin-CreER^T2^* line (*Egfr*^*ΔIEC-ER*^) ([Figure 3](#fig3){ref-type="fig"}*A*). Successful EGFR depletion in IECs was confirmed by Western blot ([Figure 3](#fig3){ref-type="fig"}*B*). The *Egfr*^*ΔIEC-ER*^ mice developed tumors comparable to *Egfr*^*ΔIEC*^ mice, and EGFR deletion had no effect on tumor number, size, and load ([Figure 3](#fig3){ref-type="fig"}*C*--*E*). These results demonstrate that EGFR inhibition in tumor cells of CRC does not have any therapeutic benefit, suggesting that the positive outcomes following EGFR inhibition in patients with metastatic CRC might be due to EGFR blockade in myeloid cells. Additionally, these results rule out the possibility of any influence of genetic adaptation and compensatory mechanism to the constitutive absence of EGFR in the *Egfr*^*ΔIEC*^ mice.Figure 3Targeting EGFR in IECs of established tumors does not lead to tumor shrinkage. (*A*) Scheme of inducible EGFR deletion in the AOM/DSS model. *Villin-CreER^T2^* activation was mediated by tamoxifen injection after tumors had developed. (*B*) Western blot confirming loss of EGFR expression in purified colonocytes from *Egfr*^*ΔIEC-ER*^ mice on Cre induction. (*C*--*E*) Analysis of tumor growth in *Egfr*^*ΔIEC-ER*^ mice and controls (n = 7--8) treated with tamoxifen showing (*C*) tumor area, (*D*) load, and (*E*) multiplicity.

EGFR Signaling in Myeloid Cells Promotes STAT3 Activation in Colorectal Tumor Cells {#sec2.4}
-----------------------------------------------------------------------------------

Independent studies have established that activation of the transcription factor STAT3 is an important factor governing CRC formation.[@bib28], [@bib39] Therefore, we assessed STAT3 activation in tumor cells by IHC for tyrosine-705-phosphorylated STAT3 (pSTAT3). In *Egfr*^*ΔIEC*^ mice and controls, we observed comparable numbers of pSTAT3-positive nuclei. In contrast, tumors from *Egfr*^*wa2/wa2*^ and *Egfr*^*ΔMYL*^ mice showed significant reduction of nuclear pSTAT3 when compared with control mice ([Figure 4](#fig4){ref-type="fig"}*A* and *B*). Moreover, *Egfr*^*wa2/wa2*^ and *Egfr*^*ΔMYL*^ tumors displayed significantly decreased expression of the antiapoptotic protein survivin, which is a downstream target of STAT3 ([Figure 4](#fig4){ref-type="fig"}*A* and *C*). Also in the *Apc*^*Min/+*^ model, *Apc*^*Min/+*^*;Egfr*^*ΔMYL*^ tumors showed significant reductions of both pSTAT3^+^ and survivin^+^ nuclei compared with controls ([Supplementary Figure 4](#figS4){ref-type="fig"}*A*--*C*), further corroborating these results. These data suggest that myeloid EGFR signaling promotes STAT3 activation and STAT3-dependent expression of survivin in intestinal tumor cells.Figure 4EGFR signaling in myeloid cells promotes colitis-associated CRC development via STAT3 activation in tumor cells. (*A*) IHC for pSTAT3 and survivin in the AOM/DSS model; *arrowheads* depict pSTAT3^+^ and survivin^+^ nuclei in tumor cells, respectively. *Scale bars* 50 μm. (*B*) pSTAT3 index (pSTAT3^+^ tumor cells/tumor area, 9--12 tumors from 3--4 different mice were counted). (*C*) Survivin index (survivin^+^ tumor cells/tumor area, 11--28 tumors from 3 different mice were counted). Data are mean ± SEM. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, *t* test. \#\#*P* \< .01, \#\#\#*P* \< .001, 1-way analysis of variance with Dunn's posttest.

EGFR Signaling in Myeloid Cells Protects From Colitis {#sec2.5}
-----------------------------------------------------

To investigate the mechanisms responsible for the observed phenotypes, we analyzed early phases of CAC development when chronic inflammation acts as a major driver. Therefore, we applied the DSS-dependent model of colitis ([Supplementary Figure 5](#figS5){ref-type="fig"}*A*) in mice lacking the EGFR in various cell types. Histological analysis showed that the colons of *Egfr*^*ΔIEC*^ mice were less inflamed than in *Egfr*^*f/f*^ mice ([Figure 5](#fig5){ref-type="fig"}*A*). In fact, *Egfr*^*ΔIEC*^ mice showed significant gain of body weight during the entire period of DSS administration when compared with the respective controls ([Figure 5](#fig5){ref-type="fig"}*B*). In contrast to *Egfr*^*ΔIEC*^ mice, DSS administration to *Egfr*^*wa2/wa2*^ and *Egfr*^*ΔMYL*^ mice resulted in extensive damage of the colonic mucosa, large ulcerated regions, and severe inflammation ([Figure 5](#fig5){ref-type="fig"}*A*), leading to significant loss of body weight when compared with controls ([Figure 5](#fig5){ref-type="fig"}*B*), which was accompanied by diarrhea. These observations confirm previous studies describing increased severity of DSS-induced colitis in *Egfr*^*wa2/wa2*^ mice.[@bib12] Our data show that EGFR signaling in myeloid cells and not in IECs protects from DSS-induced colitis.Figure 5EGFR signaling in myeloid cells protects from colitis. (*A*) Hematoxylin-eosin staining of colons of DSS-treated mice at day 10. *Scale bars* 50 μm. (*B*) Body weight during DSS treatment (n ≥6). Data are mean ± SEM. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, 2-way analysis of variance. (*C*) FITC-dextran concentration in serum as readout for intestinal permeability (n ≥5). (*D*) Number of BrdU^+^ IECs per crypt (20--30 crypts per mouse were counted, *Egfr*^*wa2/wa2*^, n = 2 mice; otherwise n = 3). (*E*--*H*) Flow cytometric analysis of the IEL and LP immune cell fraction of colons from DSS-treated mice showing percentage of live cells of (*E*) CD45^+^ hematopoietic cells, (*F*) CD11b^+^/Gr1^+^/Ly6C^lo^ granulocytes, (*G*) CD11b^+^/Gr1^int^/Ly6C^hi^ monocytes, and (*H*) CD11c^+^/CD11b^+^/CD103^−^ macrophages and dendritic cells. (*I*) IL6 serum levels in DSS-treated mice at day 7 (n ≥6). (*J*) EGFR and IL6 messenger RNA expression levels of MACS-sorted CD11b^+^ colonic myeloid cells of DSS-treated mice at day 5. Data from (*C*--*J*) are mean ± SEM. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, *t* test. \#\#*P* \< .01, \#\#\#*P* \< .001, 1-way analysis of variance with Dunn's posttest.

DSS has been described to target the crypt epithelial cells, thereby altering intestinal barrier permeability. Therefore, we investigated epithelial barrier function by oral administration of fluorescein isothiocyanate (FITC)-dextran.[@bib38] *Egfr*^*ΔMYL*^ and *Egfr*^*wa2/wa2*^ mice displayed significantly higher serum levels of FITC-dextran during colitis, demonstrating loss of barrier integrity. In contrast, *Egfr*^*ΔIEC*^ mice showed reduced levels of FITC-dextran ([Figure 5](#fig5){ref-type="fig"}*C*), confirming a previous study, which demonstrated that inhibition of EGFR prevents loss of barrier permeability.[@bib40]

Crypt cell proliferation is an important factor contributing to intestinal homeostasis and epithelial regeneration during mucosal injury. Analysis of bromodeoxyuridine (BrdU) incorporation showed significantly reduced BrdU^+^ IECs in the crypts of *Egfr*^*wa2/wa2*^ and *Egfr*^*ΔMYL*^ mice when compared with respective control mice. In contrast, the number of proliferating nuclei in *Egfr*^*ΔIEC*^ animals was comparable with controls ([Figure 5](#fig5){ref-type="fig"}*D*, [Supplementary Figure 5](#figS5){ref-type="fig"}*B*). Moreover, cleaved Caspase-3 staining in IECs did not reveal any major differences in apoptosis between *Egfr*^*ΔMYL*^ and *Egfr*^*ΔIEC*^ mice ([Supplementary Figure 5](#figS5){ref-type="fig"}*C*).

To investigate if EGFR loss on myeloid cells alters the immune cell composition during DSS-induced colitis, we separated the intestinal epithelial layer (IEL) from the LP of *Egfr*^*ΔMYL*^ and *Egfr*^*f/f*^ control mice and performed flow cytometric analysis to characterize the immune cells in the respective layers. Because DSS-induced ulcers frequently reach down to the LP ([Figure 5](#fig5){ref-type="fig"}*A*), the number of immune cells in the IEL fraction was higher than in the LP. Total CD45^+^ immune cells were overall significantly enriched in the IEL fraction of *Egfr*^*ΔMYL*^ mice ([Figure 5](#fig5){ref-type="fig"}E). The populations of TCRβ^+^ and CD4^+^/CD8^+^ T cells as well as CD19^+^ B cells and CD103^+^ dendritic cells were similar among genotypes ([Supplementary Figure 5](#figS5){ref-type="fig"}*D*--*H*). Consistent with the higher inflammation and barrier breakdown, granulocytes and monocytes, as well as macrophages/CD103^−^ dendritic cells were markedly increased in the IEL of *Egfr*^*ΔMYL*^ mice ([Figure 5](#fig5){ref-type="fig"}*F*--*H*) and monocyte numbers were also higher in the LP fraction ([Figure 5](#fig5){ref-type="fig"}*G*). Our data reveal that EGFR expression in myeloid cells is protective against DSS-induced colitis by maintaining mucosal integrity and proliferation of epithelial cells.

EGFR Signaling in Myeloid Cells Promotes STAT3 Activation Via Regulation of IL6 Production {#sec2.6}
------------------------------------------------------------------------------------------

LP cells secrete various prosurvival factors during inflammation that support epithelial regeneration. One important factor is IL6, a potent inducer of STAT3 activation.[@bib28], [@bib41] It was demonstrated that IL6/STAT3 can protect mice from DSS-induced colitis.[@bib28] Further, we recently described the importance of EGFR signaling in liver macrophages for production of IL6 in a hepatic injury model of liver cancer.[@bib30] Colons of DSS-treated *Egfr*^*ΔMYL*^ mice showed a noticeable decrease in IL6 messenger RNA expression, which is consistent with a previous study.[@bib20] In addition, these colons contained higher messenger RNA levels of chemoattractants, such as CXCL1 and CXCL2. However, the expression levels of tumor necrosis factor-α and IL1β were unchanged ([Supplementary Figure 5](#figS5){ref-type="fig"}*I*). IL6 levels were also significantly reduced in the serum of DSS-treated *Egfr*^*wa2/wa2*^ and *Egfr*^*ΔMYL*^ mice but not in *Egfr*^*ΔIEC*^ animals ([Figure 5](#fig5){ref-type="fig"}*I*). In tumor-bearing AOM/DSS-treated and *Apc*^*Min/+*^ mice, there was a nonsignificant trend of reduced IL6 in serum of *Egfr*^*ΔMYL*^ mice ([Supplementary Figure 5](#figS5){ref-type="fig"}*J*--*K*). Importantly, magnetic activated cell sorted CD11b^+^ colonic myeloid cells of DSS-treated *Egfr*^*ΔMYL*^ mice, which lacked EGFR, expressed significantly less IL6 than the respective controls ([Figure 5](#fig5){ref-type="fig"}*J*).

These data suggest that the observed phenotypes of *Egfr*^*wa2/wa2*^ and *Egfr*^*ΔMYL*^ mice in colitis and CAC formation are due to reduced IL6 production by EGFR-deficient myeloid cells.

IL6 Protects *Egfr*^*ΔMYL*^ Mice Against DSS-induced Damage {#sec2.7}
-----------------------------------------------------------

To assess the role of IL6 during colitis in *Egfr*^*ΔMYL*^ mice, we administered recombinant IL6 (rIL6) during DSS treatment ([Supplementary Figure 6](#figS6){ref-type="fig"}*A*). Indeed, exogenous IL6 protected *Egfr*^*ΔMYL*^ mice from DSS-induced weight loss, whereas *Egfr*^*wa2/wa2*^ mice were partially rescued ([Figure 6](#fig6){ref-type="fig"}*A*). Although the severity of inflammation was similar in all genotypes, administration of rIL6 significantly decreased the number of ulcers in *Egfr*^*ΔMYL*^ mice ([Supplementary Figure 6](#figS6){ref-type="fig"}*B* and *C*) and prevented from loss of epithelial barrier function ([Figure 6](#fig6){ref-type="fig"}*B*). rIL6 treatment was also able to restore epithelial proliferation during colitis ([Figure 6](#fig6){ref-type="fig"}*C*, [Supplementary Figure 6](#figS6){ref-type="fig"}*D*). STAT3 activation (pSTAT3^+^ nuclei in IECs), which was significantly reduced during DSS treatment of *Egfr*^*ΔMYL*^ mice, was fully restored on rIL6 administration ([Figure 6](#fig6){ref-type="fig"}*D* and *E*). pSTAT3 was present in CD64^+^ myeloid cells of both *Egfr*^*f/f*^ and *Egfr*^*ΔMYL*^ mice after IL6 induction ([Supplementary Figure 6](#figS6){ref-type="fig"}*E*). Taken together, we were able to rescue *Egfr*^*ΔMYL*^ mice from DSS-induced damage by administering rIL6, suggesting that myeloid EGFR signaling is responsible for IL6 release and protection of the intestinal epithelium during colitis.Figure 6IL6 protects from DSS-induced colitis. (*A*--*E*) Administration of vehicle or recombinant IL6 to DSS-treated mice. (*A*) Body weight following IL6 or vehicle administration during DSS treatment (n ≥3). (*B*) FITC-dextran concentration in serum as readout for intestinal permeability (n ≥3). (*C*) Number of BrdU^+^ IECs per crypt (30--40 crypts per mouse were counted, n = 3 mice). (*D*) pSTAT3 IHC of DSS-treated colons. *Scale bars* 50 μm. (*E*) Quantification of pSTAT3^+^ IECs per crypt (30 crypts per mouse were counted, n ≥4). (*F*--*I*) Antibody-mediated IL6 depletion during DSS-induced colitis in wild-type mice. (*F*) Body weight of IL6-depleted mice and controls during DSS treatment (n ≥3). (*G*) FITC-dextran concentration in serum as readout for intestinal permeability (n ≥7). Quantification of (*H*) BrdU^+^ IECs per crypt (30--80 crypts per mouse were counted, n ≥4) and (*I*) pSTAT3^+^ IECs per crypt (30--80 crypts per mouse were counted, n ≥3). All data are mean ± SEM. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, *t* test except (*A* and *F*), 2-way analysis of variance.

To confirm the importance of IL6 for colitis induction, we depleted IL6 from *Egfr*^*f/f*^ mice during DSS treatment to replicate the phenotype of *Egfr*^*ΔMYL*^ mice ([Supplementary Figure 6](#figS6){ref-type="fig"}*F*). Although IL6 depletion did not influence the overall colitis severity, a mild increase in ulcers was observed ([Supplementary Figure 6](#figS6){ref-type="fig"}*G* and *H*). However, IL6-depleted mice showed significant weight loss compared with isotype controls during DSS treatment ([Figure 6](#fig6){ref-type="fig"}*F*). They further displayed a significant increase of intestinal barrier permeability ([Figure 6](#fig6){ref-type="fig"}*G*). This defect in gut barrier integrity was further substantiated by a strong reduction in proliferation of crypt cells ([Figure 6](#fig6){ref-type="fig"}*H*, [Supplementary Figure 6](#figS6){ref-type="fig"}*I*). Additionally, we observed a significant decrease in nuclear pSTAT3 signaling in IL6-depleted mice ([Figure 6](#fig6){ref-type="fig"}*I*). In summary, these observations suggest that IL6 is required to prevent DSS-induced damage and that its depletion establishes a phenotype similar to *Egfr*^*ΔMYL*^ mice.

Discussion {#sec3}
==========

To date, the absence of *KRAS* and *NRAS* (exons 2, 3, and 4) mutations serves as the only clinically approved predictive biomarker for EGFR-targeted therapies of metastatic CRC. Besides *RAS*, mutations in genes like *BRAF* and *PIK3CA* have been suspected to predict unresponsiveness of anti-EGFR therapy. However, several clinical studies delivered partly conflicting results and, as these mutations occur in a rather low percentage of patients, this highlights the need for a more reliable strategy for patient stratification.[@bib42]

We show for the first time that EGFR expression in myeloid cells is a negative prognostic factor for overall survival of patients with metastatic CRC and further demonstrate a pro-tumorigenic role of myeloid EGFR in mouse models of AOM/DSS-induced and *Apc*^*Min*^-dependent intestinal tumorigenesis, mimicking early stages of human disease. In a previous study of HCC, we made a similar discovery. Most importantly, we demonstrated a correlation between EGFR expression in Kupffer cells/liver macrophages and poor prognosis for patients with HCC,[@bib30] suggesting that the ability of EGFR to support tumor formation via myeloid cells might extend to other inflammation-associated cancers. Intriguingly, whereas the presence of CD68^+^/EGFR^+^ macrophages in patients with CRC did not affect overall survival, the number of CD11b^+^/EGFR^+^ myeloid cells was a bad prognostic factor for overall survival of patients with metastatic disease. This highlights that cells other than macrophages, such as granulocytes or myeloid suppressor cells, might be responsible for the observed phenotypes. These myeloid cells might need EGFR signaling for the secretion of immune-modulatory cytokines, such as IL6, to promote tumor growth. Consistent with this, *Apc*^*Min*^ mice have fewer polyps in an IL6-deficient background.[@bib43] Our findings offer an explanation for the nonresponsiveness of more than 50% of patients with CRC with wild-type *RAS* to EGFR-targeted treatment.[@bib42] Based on our results, we predict that patients with EGFR^+^ myeloid cells respond to anti-EGFR treatment (55% in our patient cohort), whereas patients in whom EGFR is expressed only in tumor cells (45% in our patient cohort), might not benefit. Interestingly, the distribution of CD11b^+^/EGFR^+^ myeloid cells was similar among the 18 patients with known RAS status, suggesting that the presence of oncogenic RAS in tumor cells does not influence EGFR expression on myeloid cells. Because patients with mutant RAS in tumor cells do not respond to anti-EGFR treatment, it is possible that EGFR inhibitors are effective only if they can act on both tumor and myeloid cells. This situation would occur only in patients with CRC with wild-type RAS in whom EGFR is expressed on tumor as well as on myeloid cells. Clinical follow-up studies are necessary to evaluate a patient stratification strategy based on myeloid EGFR expression, ultimately providing better personalized application of EGFR-directed therapy.

The role of EGFR during early and late stages of CRC is highly complex and likely depends on time and cell type of expression. In previous studies based on the *Egfr*^*wa2/wa2*^ model, it was postulated that EGFR expression in IECs is necessary for colon cancer formation.[@bib15], [@bib16], [@bib17], [@bib18] However, our results demonstrate that EGFR signaling is required in myeloid cells for CRC development, as EGFR deletion in IECs does not affect tumor growth. Thus, impaired CAC and CRC formation in *Egfr*^*wa2/wa2*^ mice is likely due to attenuated EGFR signaling in the myeloid compartment. Dubé et al,[@bib11] however, show that EGFR inhibition accelerates CAC development in *Egfr^wa5/+^* mice. These results are contradictory to our results and the results of Dougherty et al,[@bib15] which were obtained with *Egfr*^*wa2/wa2*^ mice, pointing toward a broader and even dominant-negative effect of the Wa5 variant of EGFR. Moreover, factors like mouse strain, intestinal microbiome, diet, and experimental setup also can affect the outcome.

We further deleted EGFR exclusively on IECs, clearly and unequivocally showing that it is dispensable for tumor formation in both AOM/DSS-induced and *Apc*^*Min*^-dependent intestinal tumorigenesis. This is supported by previous investigations, in which EGFR expression on IECs is dispensable during colitis and after surgical resection.[@bib13], [@bib19] Last, lack of EGFR in IECs of *Egfr*^*ΔIEC*^ mice also may contribute to greater barrier integrity, as EGFR inhibition has been shown to prevent increase in barrier permeability.[@bib40], [@bib44] Besides showing that EGFR is dispensable in IEC during tumor initiation, we also demonstrate that it is not essential for tumor progression, as EGFR ablation on IECs had no effect on preexisting tumors, when we recapitulated the therapeutic situation. These results clearly demonstrate that EGFR deletion in tumor cells did not affect tumor growth.

Colitis, which can ultimately lead to tumor formation, is a complicated process involving a variety of immune cells and a network of cytokines and chemokines. We demonstrate that EGFR ablation in myeloid cells aggravates DSS-induced colitis, which can be rescued by IL6 administration. Results of Lu et al[@bib20] describe that EGFR deletion in myeloid cells improves colitis via increased IL10 production. The variation in observations might be explained by differences in concentration and duration of DSS treatment, as well as by distinct time points of analysis and different *Egfr*^*f/f*^ lines; however, they reported impaired IL6 transcription during colitis after myeloid-specific EGFR deletion, thus confirming our results. IL6 is known to be primarily produced by cells of the innate immune system, such as myeloid cells, during an immune response.[@bib3] In chemically induced HCC, we previously showed that EGFR expression in Kupffer cells induces IL6 production.[@bib30] In CAC, IL6 stimulates survival and proliferation of IECs.[@bib28] Supporting this, we here observe that selective deletion of EGFR in myeloid cells, but not in IECs, critically impairs systemic IL6 levels during colitis, which is coupled with a proliferation defect of IECs. This is in line with observations in *IL6*^*−/−*^ mice.[@bib28] Thus, our results suggest that the protective function exerted by EGFR on IECs might occur indirectly via activation of EGFR signaling in myeloid cells with subsequent IL6 secretion.

Activation of STAT3 signaling by IL6 family cytokines is required for CRC formation in AOM/DSS-dependent mouse models and protects from colitis.[@bib28], [@bib39] Here, we prevent DSS-induced colitis by restoring systemic IL6 levels in *Egfr*^*ΔMYL*^ mice, thereby reestablishing STAT3 signaling in IECs, which restores IEC proliferation. Our observations describe the requirement of myeloid EGFR signaling for protective IL6 production during intestinal inflammation. In the *Apc*^*Min/+*^ model, STAT3 signaling is essential for promoting tumorigenesis during the initial stages.[@bib45] We could observe a reduction of the overall tumor burden in *Apc*^*Min/+*^*;Egfr*^*ΔMYL*^ mice going along with pSTAT3 reduction, which further supports our model of EGFR-dependent IL6 signaling as tumor promoter. In line with our findings in colitis, the reduced nuclear pSTAT3 levels in the AOM/DSS-induced tumors of *Egfr*^*ΔMYL*^ mice point to a systemic IL6 deficiency. This is linked with a decreased expression of the STAT3 target gene survivin and increased apoptosis, which further leads to reduced tumor size.

In conclusion, our results imply that EGFR-expressing myeloid cells might be a novel prognostic marker for CRC, providing the possibility to stratify patients who can really benefit from EGFR-directed therapy and to spare others from ineffective treatment and its painful side effects.

Supplementary Materials and Methods {#appsec1}
===================================

Mice {#appsec1.1}
----

All animal experiments conducted were compliant with federal laws and guidelines of the Medical University of Vienna. *Egfr*^*f/f*^*,*[@bib46] *Villin-Cre* and *Villin-CreER*^*T2*^,[@bib47] *LysM*^*Cre/+*^,[@bib48] and *Apc*^*Min/+*^[@bib49] mice and their genotyping by polymerase chain reaction (PCR) were previously described. *Egfr*^*+*^, *Egfr*^*f*^, and *Egfr*^*Δ*^ alleles were detected by PCR using primers R4: GCCTGTGTCCGGGTCTCGTCG, R6: CAACCAGTGCACCTAGCCTGG, Egfr-fwd1: AAGTTTAAGAAACCCCGCTCTACT. *Villin-Cre* mice were obtained on a DBA/2;C57BL/6J background and bred to a mixed 129/Sv;C57BL/6 genetic background. Littermates with EGFR expression (*Egfr*^*f/f*^*, Villin-Cre;Egfr*^*f/+*^*, LysM*^*Cre/+*^*;Egfr*^*f/+*^*, Egfr*^*f/+*^, and *Egfr*^*wa2/+*^ mice) were used as controls to the respective EGFR-deleted animals. Mice from the *Apc*^*Min/+*^ model were analyzed at the age of 3 months. All further experiments were performed in mice between 6 and 8 weeks of age.

Southern Blot Analysis {#appsec1.2}
----------------------

Intestinal epithelial cells (IECs) were isolated as described.[@bib50] Genomic DNA was extracted from IECs by salt and ethanol precipitation; 10 μg DNA was digested with HindIII (New England BioLabs, Ipswich, MA) and probed using an XbaI/HindIII digested fragment from intron 1 of *Egfr* as described.[@bib46]

Western Blot, Enzyme-Linked Immunosorbent Assay, and Quantitative Reverse Transcriptase PCR Analysis {#appsec1.3}
----------------------------------------------------------------------------------------------------

IECs were isolated as described previously and lysed in radioimmunoprecipitation assay buffer. Proteins were separated by sodium dodecyl sulfate--polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA). Western blot analysis was performed as described.[@bib51] Antibodies used were EGFR (06-847, EMD; Millipore) and glyceraldehyde-3-phosphate dehydrogenase (5174; Cell Signaling, Danvers, MA). Interleukin (IL)6 enzyme-linked immunosorbent assay was carried out using the Mouse IL6 enzyme-linked immunosorbent assay Ready-SET-Go.

Bone marrow--derived macrophages were isolated as previously described.[@bib52] Total RNA isolation from the distal colon and bone marrow--derived macrophages was performed as described.[@bib53] Complementary DNA (cDNA) synthesis was performed using ProtoScript II Reverse Transcriptase (NEB, Ipswich, MA). Total RNA isolation from CD11b^+^ colonic macrophages was performed using the miRNeasy Micro Kit (Qiagen, Hilden, Germany). cDNA synthesis was done using SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA). Quantitative reverse transcriptase PCR reactions and analysis were done as described.[@bib53] Primer sequences for IL6, IL1β and cyclophilin have been previously reported.[@bib54] Further primers used were tumor necrosis factor-α-F: ATGAGAAGTTCCCAAATGGCC, tumor necrosis factor-α-R: TCCACTTGGTGGTTTGCTACG, CXCL1-F: GCCAATGAGCTGCGCTGT, CXCL1-R: CCTTCAAGCTCTGGATGTTCTTG, CXCL2-F: ATCCAGAGCTTGAGTGTGACGC, CXCL2-R: AAGGCAAACTTTTTGACCGCC, EGFR-F: TTGGAATCAATTTTACACCGAAT, EGFR-R: GTTCCCACACAGTGACACCA, TBP-F: GGGGAGCTGTGATGTGAAGT, TBP-R: CCAGGAAATAATTCTGGCTCAT.

Histology {#appsec1.4}
---------

Mice were injected with 10 mg/kg bromodeoxyuridine (BrdU) 2.5 hours before they were euthanized. The colons were extracted, flushed with ice-cold phosphate-buffered saline (PBS), fixed overnight at 4°C in neutral buffered 4% formaldehyde as "swiss rolls," which were further dehydrated, embedded in paraffin, and sectioned for subsequent histological analysis. Colitis severity was scored as described.[@bib55] Mouse tumor stage was scored and graded by a pathologist in a blinded manner according to described criteria.[@bib50] tyrosine-705-phosphorylated STAT3^+^ epithelial cell counting in the colitis model was performed as described.[@bib50] Starting from the distal part of the colon, for each mouse, tyrosine-705-phosphorylated STAT3^+^ cells were counted in more than 30 whole crypts.

Immunohistochemistry and Immunofluorescence {#appsec1.5}
-------------------------------------------

Sections were dewaxed, rehydrated and subjected to antigen recovery using either citrate buffer pH 6.1 or pH 9 (Dako, Glostrup, Denmark). For immunohistochemistry, endogenous peroxidase was quenched by incubation with 3% hydrogen peroxide in Tris-buffered saline, followed by blocking (10% goat serum, 2% bovine serum albumin, 0.1% Tween in Tris-buffered saline). Sections were then incubated overnight with antibodies against pTyr705-STAT3 (9145), Survivin (2808), cleaved Caspase-3 (9661; all Cell Signaling), Lysozyme (A0099; Dako), EGFR (sc-03; Santa Cruz, Santa Cruz, CA) or Synaptophysin (GTX100865; GeneTex, Irvine, CA). All sections were further treated with SignalStain Boost (Cell Signaling) and AEC Chromogen/Substrate Bulk Kit (ID Labs, London, UK) and counterstained with hematoxylin.

For immunofluorescence (IF) BrdU staining, sections were treated with 2N hydrochloric acid after antigen recovery, blocked as described previously, incubated with BrdU antibody (347580; BD Biosciences, San Jose, CA) and secondary antibody (A-11018; Invitrogen, Carlsbad, CA) and counterstained with 4′,6-diamidino-2-phenylindole.

For CD11b/EGFR, CD11b/pEGFR, or CD68/EGFR IF staining of human paraffin slides, sections were incubated briefly with 3% H~2~O~2~ in methanol after antigen recovery followed by biotin block (E-21390; Thermo Fisher Scientific). After blocking, (5% horse serum, 1% bovine serum albumin, 0.1% Triton in PBS), sections were incubated overnight with antibodies against EGFR (4267; Cell Signaling), pTyr1068-EGFR (API 300 AA; Biocare Medical, Pacheco, CA), CD68 (M0814; Dako) and CD11b (IM0190; Beckman Coulter, Brea, CA).

After 1 hour of secondary antibody incubation, each tissue microarray core was completely photographed using a Nikon (Vienna, Austria) Eclipse 80i fluorescence microscope at ×200 magnification or scanned using the Panoramic Digital Slide Scanner or Tissuegnostics (Vienna, Austria) TissueFAXS at the Core Facility Imaging of the Medical University of Vienna. Images were assembled with ImageJ (<http://imagej.nih.gov/ij/>; provided in the public domain by the National Institutes of Health, Bethesda, MD). Counting of CD11b^+^/EGFR^+^ and CD11b^+^/pEGFR^+^ cells was performed manually for each core using Adobe Photoshop (Adobe Systems, Inc, San Jose, CA). Analysis of CD68^+^/EGFR^+^ cells was carried out using Definiens image analysis software (Munich, Germany).

For IF on mouse paraffin slides, the same conditions as for human paraffin slides were applied. Sections were incubated with antibodies against CD64 (139303; Biolegend, San Diego, CA), EGFR (4267), and pTyr1068-EGFR (3777, both Cell Signaling).

Flow Cytometric Analysis and Magnetic Cell Sorting {#appsec1.6}
--------------------------------------------------

For subsequent flow cytometric analysis, colitis was induced in *Egfr*^*ΔMYL*^ and *Egfr*^*f/f*^ control mice by dextran sodium sulfate administration. Analysis was done at day 10 using 5 mice per genotype. The fraction of intraepithelial lymphocytes and lamina propria cells were isolated for flow cytometric analysis as previously described.[@bib56] Magnetic cell sorting of CD11b^+^ myeloid cells from the colon of dextran sodium sulfate--treated *Egfr*^*ΔMYL*^ and *Egfr*^*f/f*^ control mice was performed at day 5 using ≥5 mice per genotype. The colon was cut into pieces and digested in RPMI medium with 10% fetal calf serum (FCS), 1% penicillin/streptomycin, 1 mg/mL Collagenase VIII (Sigma-Aldrich, St. Louis, MO) and 1 mg/mL DNase I (Sigma-Aldrich) for 1 hour at 37°C shaking at 300 rpm. Samples were filtered through a 70-μm cell strainer and washed once with Hank's balanced salt solution containing 10% FCS, 1% penicillin/streptomycin, and 5 mM EDTA and twice with PBS containing 5% FCS, 5 mM EDTA, and 20 μg/mL DNase I. Myeloid cell fractions were enriched by density gradient centrifugation as described.[@bib57] Magnetic cell sorting was carried out using a biotinylated CD11b antibody (M1/70; Biolegend) and IMag Streptavidin Particles Plus-DM (BD Biosciences). Sorting quality was tested by flow cytometric analysis, revealing that more than 95% of sorted live cells were CD45^+^/CD11b^+^.

Cell suspensions were stained using fluorescently labeled antibodies for 30 minutes at 4°C after blocking with Fc-block (CD16/CD32, 93; Biolegend). The following antibodies were used: TCRβ (H57--597), CD4 (GK1.5), CD8a (53.6--7), CD19 (6D5), CD45 (30-F11, APC-Cy7), Gr1 (RB6--8C5), Ly6G (1A8), F4/80 (BM8), CD11b (M1/70), CD11c (N418; all Biolegend), CD45 (30-F11, PECF594), TCRδ (GL-3), CD44 (IM7), CD103 (2E7), CD335 (29A1.4; all BD Biosciences), Ly6C (HK1.4), I-A/I-E (MHCII, M5/114; all Thermo Fisher Scientific). Data were acquired on LSRFortessa flow cytometer (BD Biosciences, Schwechat, Austria) and analyzed with FloJo software (FlowJo, LLC, Ashland, OR).

Intestinal Barrier Assessment {#appsec1.7}
-----------------------------

Intestinal barrier permeability was assessed as described.[@bib58] Briefly, food and water were withdrawn 4 hours before oral gavage with 60 mg/kg fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich). FITC levels were determined in the serum 4 hours after gavage by absorption at 488 nm using standard dilutions of FITC-dextran as reference.

Statistics {#appsec1.8}
----------

### Human material {#appsec1.8.1}

For human samples, differences between categorical data were measured by χ^2^ test. Differences between continuous variables were investigated by Mann-Whitney *U* test and Kruskal-Wallis test, when appropriate. Kaplan-Meier method was used to estimate median overall survival time, and *P* values were calculated using log-rank test. All tests were 2-sided, with *P* \< .05 considered to indicate statistical significance. All statistical analyses were carried out using the SPSS package (IBM Corporation, Chicago, IL).

### Mouse experiments {#appsec1.8.2}

The mouse experiments were not randomized and the investigators were not blinded during experiments and outcome assessment. Sample size calculation: For tumor studies, we considered 10 mice per group to detect a relevant difference in means of 1.5 within-group standard deviations at a 2-sided significance level of .05 and a power of 90%, which ensures 80% power in case of a 20% drop-out rate. Mouse experiments were performed as indicated in the figure legends. Quantifications on blinded histological samples were performed by counting/measuring microscopic fields (high-powered fields where indicated) as indicated in the legends. Data are presented as mean ± SEM. Statistical significance was calculated by unpaired Student *t* test (comparison of 2 experimental groups) or 1-way analysis of variance followed by multiple comparison Dunn's posttest (comparison of 3 or more experimental groups) for parametric observations, whereas for discontinuous observations, such as scores for colitis and tumors, significance was evaluated by Mann-Whitney *U* or Kruskal-Wallis test. Significance of tumor penetrance was calculated by Fisher's exact test. Each tumor measurement contributed by 1 animal is the mean value over several gastrointestinal sections. All calculations were performed using the GraphPad Prism software (San Diego, CA). A 2-sided *P* \< .05 was considered statistically significant.

Author names in bold designate shared co-first authorship.Supplementary Figure 1EGFR expression and phosphorylation in tumor and stromal cells of patients with CRF. (*A*) Representative images used for IHC scoring of EGFR expression (−, +, ++, +++) in tumor and stromal cells (*upper panels*). Intensities of EGFR determined by IF (*lower panels*) were comparable with IHC. (*B*) Distribution of tumors according to the percentage of CD68^+^/EGFR^+^ (n = 118), CD11b^+^/EGFR^+^ (n = 108), and CD11b^+^/pEGFR^+^ (n = 113) cells in the total CD68^+^ or CD11b^+^ stromal population, respectively, determined by IF double staining shown in (*C*) and [Figure 1](#fig1){ref-type="fig"}*F*. (*C*) IF double staining on CRC samples shows presence of CD11b^+^/pEGFR^+^ cells in the stroma. *Scale bars* 50 μm. (*D*) Patients were divided into 2 groups: low (0 to \<1%) and high (≥1%), according to percentage of CD11b^+^/pEGFR^+^ cells in the total CD11b^+^ stromal population (n = 113), determined by IF shown in (*C*).Supplementary Figure 2EGFR expression and intestinal development. (*A*) EGFR IHC staining on DSS-treated colons of indicated mice, *black arrowheads* depict IECs, *white arrowheads* depict LP cells. (*B*) PCR and (*C*) Southern blot analysis of genomic DNA from purified colonocytes showing successful Cre-mediated recombination of the floxed *Egfr* allele in *Egfr*^*ΔIEC*^ mice. (*D*) Western blot confirming absence of EGFR protein in purified colonocytes from *Egfr*^*ΔIEC*^ mice. (*E*) PCR analysis of purified bone marrow--derived macrophages showing successful Cre-mediated recombination of the floxed *Egfr* allele in *Egfr*^*ΔMYL*^ mice. (*F*) Western blot confirming loss of EGFR protein in bone marrow--derived macrophages from *Egfr*^*ΔMYL*^ mice. (*G*) Quantitative reverse transcriptase PCR analysis of EGFR mRNA expression of bone marrow--derived macrophages showing absence of EGFR in *Egfr*^*ΔMYL*^ mice. mRNA expression levels were normalized to TBP (*Egfr*^*f/f*^ n = 2, *Egfr*^*ΔMYL*^ n = 5). (*H*) Hematoxylin-eosin (H&E) and periodic acid-Schiff (PAS) staining on colon sections, *arrowheads* depict goblet cells. Giemsa staining on small intestine, *arrowheads* point to refractive eosinophilic granules of paneth cells. IHC staining for lysozyme and synaptophysin, *arrowheads* demonstrate presence of paneth cells and enteroendocrine cells, respectively. *Scale bars* 50 μm.Supplementary Figure 3EGFR signaling in myeloid cells in the AOM/DSS-dependent model of CAC. (*A*) Scheme of AOM/DSS-administration to induce CAC; 7.5 mg/kg AOM was injected IP; DSS was given in drinking water (*black areas*) followed by regular water (*white areas*). (*B*) IF double staining for CD64 and pEGFR. *Arrowheads* depict presence of CD64^+^/pEGFR^+^ cells. (*C*) Grading of neoplastic lesions. Percentage of low-grade (LG) and high-grade (HG) adenomas as well as adenocarcinomas in indicated genotypes (n ≥4). (*D*) Hematoxylin-eosin stainings of different lesion grades as indicated. (*E*) Histological assessment of inflammation scores on colon sections of AOM/DSS-treated mice (n ≥4). (*F*) BrdU IF and cleaved Caspase-3 IHC stainings, *arrowheads* depict BrdU^+^ and cleaved Caspase-3^+^ nuclei in tumor cells, respectively. *Scale bars* 50 μm.Supplementary Figure 4EGFR signaling in myeloid cells promotes *Apc*^*Min*^-driven CRC development via STAT3 activation in tumor cells. (*A*) IHC staining for pSTAT3 and survivin in the *Apc*^*Min/+*^ model, *arrowheads* depict pSTAT3^+^ and survivin^+^ nuclei in tumor cells, respectively. *Scale bars* 50 μm. (*B*) pSTAT3 index was defined by dividing the number of pSTAT3^+^ tumor cells by the tumor area in *Apc*^*Min/+*^ mice (13--25 tumors from 3--4 different mice were counted). (*C*) Survivin index was defined by dividing the number of survivin^+^ tumor cells by area of tumors in *Apc*^*Min/+*^ mice (9--30 tumors from 3--5 different mice were counted). Data are mean ± SEM. \*\*\**P* \< .001, *t* test. \#*P* \< .05, \#\#\#*P* \< .001, 1-way analysis of variance with Dunn's posttest.Supplementary Figure 5EGFR signaling in myeloid cells protects from colitis. (*A*) Scheme of the DSS-dependent colitis model. On day 10, mice were starved for 4 hours before oral administration of FITC-dextran. (*B*) BrdU IF staining, *arrowheads* depict BrdU^+^ IECs. *Scale bars* 50 μm. (*C*) Quantification of cleaved Caspase-3^+^ IECs per crypt as readout for apoptosis (30 crypts per mouse were counted, n = 3--4). (*D*--*H*) Flow cytometric analysis of the IEL and LP immune cell fraction of colons from DSS-treated mice shows percentage of live cells of (*D*) TCRβ^+^ αβ T cells, (*E*) ratio of CD4^+^/CD8^+^ T cells, (*F*) CD19^+^ B cells, (*G*) CD11c^+^/CD11b^+^/CD103^+^, and (*H*) CD11c^+^/CD11b^-^/CD103^+^ dendritic cell subsets. (*I*) Quantitative reserve transcriptase PCR analysis of IL6, CXCL1, CXCL2, tumor necrosis factor-α, and IL1β mRNA expression. Relative mRNA expression levels were determined in whole colon tissues on day 10 (n = 3) and normalized to Cyclophilin. Data are mean ± SEM. (*J*--*K*) IL6 serum levels in endpoint mice with (*J*) AOM/DSS treatment (n = 4 for *Egfr*^*wa/wa*^, otherwise n = 7) and (*K*) the *Apc*^*Min*^ background (n ≥7). Data are mean ± SEM. \#*P* \< .5, 1-way analysis of variance with Dunn's posttest.Supplementary Figure 6IL6 protects from DSS-induced colitis. (*A*) Scheme of IL6 or vehicle administration during colitis induction, on day 10 mice were starved for 4 hours before oral FITC-dextran administration. (*B* and *C*) Histological assessment of (*B*) number of ulcers and (*C*) inflammation scores on colon sections of mice supplemented with IL6 during DSS treatment. Data are mean ± SEM. \*\*\**P* \< .001, *t* test. (*D*) BrdU IF stainings, *arrowheads* depict BrdU^+^ IECs. (*E*) IF double staining for pSTAT3 and CD64. *Arrowheads* depict presence of pSTAT3^+^/CD64^+^ cells. (*F*) Scheme of anti-IL6 or isotype control antibody administration during colitis induction, on day 10 mice were starved for 4 hours before oral FITC-dextran administration. (*G* and *H*) Histological assessment of number of ulcers (*G*) and inflammation scores (*H*) on colon sections of IL6-depleted mice (n ≥6). Data are mean ± SEM. (*I*) BrdU IF staining, *arrowheads* depict BrdU^+^ IECs. *Scale bars* 50 μm.

Supplementary Material {#appsec2}
======================

Supplementary Table 1
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